MedTrace Logo

Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites

NCT00501566 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2007-07-16

No results posted yet for this study

Summary

The primary objective is to determine the optimal dose or range of doses of SR121463B for the treatment of ascites when used concomitantly with a standard dose regimen of spironolactone and furosemide.

The secondary objective is to determine the tolerability of different fixed doses of SR121463B over a 14 day treatment period in cirrhotic ascites.

Conditions

Interventions

DRUG

satavaptan (SR121463B)

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Completion
2005-01-31

Countries

  • Argentina
  • Australia
  • Belgium
  • Canada
  • Croatia
  • Czechia
  • France
  • Germany
  • Hungary
  • Italy
  • Romania
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00501566 on ClinicalTrials.gov